Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
(Date:5/22/2015)... 22, 2015 According to a ... Product (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, ... Cytometry), by End Users - Global Forecast to 2020", ... expected to reach $736.85 Million by 2020 from $452.36 ... Browse 71 market data Tables and ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... HAYWARD, Calif., April 17, 2012 Solta Medical, Inc. (NASDAQ: ... aesthetics market, today confirmed its plan to release the Company,s ... after market close on Tuesday, May 1, 2012. The Company will ... 1, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) ...
... the worldwide leader in dental esthetics, announced today that its ... new Official Whitening Fundraising Partner of Give Back a Smile ... Dentistry (AACD) Charitable Foundation to restore the damaged ... Since the launch of GBAS in 1999, ...
Cached Medicine Technology:Solta Medical to Report First Quarter 2012 Results Release and Host Conference Call on May 1 2Heraeus' Venus White® Brand Named the Official Whitening Fundraising Partner of Give Back a Smile 2
(Date:5/22/2015)... (PRWEB) May 22, 2015 Omar Ahmad ... selected to participate in the 2015 Congress of Future ... described as a gathering of “America’s highest achieving high ... areas of healthcare, set new goals and learn better ... a live surgery, during which we can ask the ...
(Date:5/22/2015)... 22, 2015 Hands On HealthCare Massage ... 2015, the Annual One Day Sale on Massage ... On HCMT offers drastically reduced certificates one day a year. ... enough sessions, through what used to be the slowest time ... the community as well. This once a year occurrence has ...
(Date:5/22/2015)... DC (PRWEB) May 22, 2015 Family, ... University Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. Leffall, ... , The luncheon began after Grand Rounds in the ... Leffall, waited anxiously outside the auditorium, trying to keep ... him, but if he sees me, he’ll know something ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... Seattle, WA (PRWEB) May 22, 2015 According ... adults of all generations are equally as likely to worry ... (72% Millennials, 75% Gen X, 77% Boomers, 69% Silent Generation), ... (45%) agree they are scared of aging, particularly Millennials (47%), ... online by Harris Poll in April, 2015 among more than ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... CME LLC (http://www.CMELLC.com ), a,leading provider of ... announced it has been granted five-year full approval ... sponsor of,continuing medical education for APA members. ... part of the APA,s,Continuing Education in Psychology (CEP) ...
... SUNNYVALE, Calif., October 24, 2007 The Parkinsons Institute ... nicotine treatment reduces medication-induced dyskinesias by as much as ... by senior research scientist, Maryka Quik, Ph.D., the research ... Annals of Neurology. , Levodopa, the most ...
... (Nasdaq: ANSV ) will announce financial results for ... November 1, 2007 and will hold a,webcast teleconference at ... will discuss financial results from the third quarter 2007,as ... pipeline, recent,events and milestones. Interested parties can listen ...
... drives ... administrative expense ratio continues to improve, declining ... shares of its common stock during the ... quarter for $2.4 billion, INDIANAPOLIS, Oct. 24 WellPoint, Inc. (NYSE:,WLP) today announced ...
... BEIJING, Oct. 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ... diagnostic products and high intensity focused ultrasound tumor,therapy systems, today announced the following ... ... Location ...
Cached Medicine News:Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:CME LLC Granted Five-Year Full Approval by the American Psychological Association 2Health News:Parkinson's Institute research shows that nicotine reduces levodopa-induced dyskinesias 2Health News:Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007 2Health News:WellPoint Reports Third Quarter 2007 Results 2Health News:WellPoint Reports Third Quarter 2007 Results 3Health News:WellPoint Reports Third Quarter 2007 Results 4Health News:WellPoint Reports Third Quarter 2007 Results 5Health News:WellPoint Reports Third Quarter 2007 Results 6Health News:WellPoint Reports Third Quarter 2007 Results 7Health News:WellPoint Reports Third Quarter 2007 Results 8Health News:WellPoint Reports Third Quarter 2007 Results 9Health News:WellPoint Reports Third Quarter 2007 Results 10Health News:WellPoint Reports Third Quarter 2007 Results 11Health News:WellPoint Reports Third Quarter 2007 Results 12Health News:WellPoint Reports Third Quarter 2007 Results 13Health News:WellPoint Reports Third Quarter 2007 Results 14Health News:WellPoint Reports Third Quarter 2007 Results 15Health News:WellPoint Reports Third Quarter 2007 Results 16Health News:WellPoint Reports Third Quarter 2007 Results 17Health News:WellPoint Reports Third Quarter 2007 Results 18Health News:WellPoint Reports Third Quarter 2007 Results 19Health News:WellPoint Reports Third Quarter 2007 Results 20Health News:WellPoint Reports Third Quarter 2007 Results 21Health News:WellPoint Reports Third Quarter 2007 Results 22Health News:WellPoint Reports Third Quarter 2007 Results 23Health News:WellPoint Reports Third Quarter 2007 Results 24Health News:China Medical Technologies to Participate in Investor Events in November 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: